Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
To investigate whether Budesonide/Formoterol (Symbicort ®) therapy can improve heart function
at rest by decreasing lung hyperinflation in patients with COPD (Chronic Obstructive
Pulmonary Disease).
Phase:
Phase 4
Details
Lead Sponsor:
Brigham and Women's Hospital
Collaborator:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate